Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
Summary
The purpose of this phase I/II study is to evaluate the safety, efficacy, and feasibility of combination therapy with entinostat and ZEN003694 in patients with lymphoma, or solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05053971
Study ID: NCI-2021-09727
Trial Phase: Phase I/II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Entinostat, ZEN-3694